Scinovex
article Open Access

Evaluation of interleukin-6 in patients with breast cancer in Sokoto-Nigeria

International Journal of Immunology Research · 2019 · Vol. 1(1) · pp. 01–04

Abstract

Introduction: Breast cancer is cancer that develops from breast tissue, Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, nipple discharge, or a red, scaly patch on the skin. Cancer has become a major source of morbidity and mortality globally. In 2008, of the 12.7 million new cases and 7.6 million cancer-related deaths, 56% of these newly reported cases occurred in developing countries. Interleukin 6, a pleiotropic cytokine has both tumour-promoting and tumour inhibitory effects, It plays an important role in cancer pathogenesis Aims and Objectives: The study aimed to evaluate the serum levels of interleukin 6 in breast cancer patients and normal controls. This is to access if an increase in the level of IL-6 is associated with the incidence of breast cancer. Materials and Methods: The study included a total of ninety (90) subjects; sixty (60) breast cancer patients and thirty (30) normal controls. Serum interleukin 6 was analysed using sandwich ELISA obtained from Melsin Medical Corporation limited. CAT. NO: EKHU_0140. LOT #:M20180709. A p-value ≤ 0.05 was considered statistically significant. Results: The findings of this study shows a significant increase in IL-6 with breast cancer patients (16.080 ± 0.71) compared to normal controls (10.310 ± 1.08) (P

Cancer, Lipids, and MetabolismAdipokines, Inflammation, and Metabolic DiseasesChemokine receptors and signalingBreast cancerMedicineCancerInternal medicineIncidence (geometry)OncologyInterleukin 6Cytokine
Citations
1
FWCI
0.00
field-weighted impact
References
0
Percentile
17%
vs. same field & year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Evaluation of interleukin-6 in patients with breast cancer in Sokoto-Nigeria · Scinovex